$FEMY consolidation ahead of earnings, with FemBloc pivotal trial and updates in focus. Double normal volume traded, hinting at new attention.

Femasys Advances FemBloc Toward U.S. Approval with Initiation of Pivotal Trial Enrollment Femasys (NASDAQ: FEMY) has begun patient enrollment in the FDA-authorized FINALE pivotal trial of FemBloc, a first-of-its-kind non-surgical permanent birth control. The move follows an FDA Investigational Device Exemption approval and positive earlier clinical data. FemBloc is already approved and commercialized in Europe and select countries outside the U.S., and completion of FINALE is expected to support a future U.S. regulatory submission.

#FEMY Femasys Advances FemBloc Toward U.S. Approval with Initiation of Pivotal Trial Enrollment

www.stocktitan.net/news/FEMY/femasys-advanc...

Femasys Announces FemBloc® Permanent Birth Control Has Achieved MDSAP Certification, Advancing Global Market Access Femasys (NASDAQ: FEMY) announced that its FemBloc permanent birth control system achieved MDSAP certification on Feb. 26, 2026, enabling accelerated regulatory and commercial execution across the United States, Canada, Japan, Australia, and Brazil. The certification supports pivotal trial readiness toward a future PMA submission and strengthens manufacturing credibility for global expansion.

#FEMY Femasys Announces FemBloc® Permanent Birth Control Has Achieved MDSAP Certification, Advancing Global Market Access

www.stocktitan.net/news/FEMY/femasys-announ...

昨日天覧山へ軽く登って
来ました。

いい天気でしたが
残念ながら富士山は
見えなかったです。

株主優待を使って
予約した
麓のレストラン
Femy_(フェミー）で食事を
してまいりました。
体に優しい美味しいご飯。
軽く調理して
仕上げは薪で焼き上げる
そうです。
薪の煙のいい香りしました。
お値段は少しお高め。
2000円の優待券を
プラスして3500円の
コースメニューを
食べてまいりました。
とても美味しく
元気が出ました。

外に目を向けると
登山者が歩いてるのが
見えます。

#Femy_
#レストラン

Femasys Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement Femasys (NASDAQ: FEMY) said Nasdaq granted a 180-calendar day extension on January 13, 2026 to regain compliance with the minimum $1.00 bid price requirement.The company has until July 13, 2026 to achieve a closing bid of $1.00 or higher for at least ten consecutive business days to regain compliance. Nasdaq noted Femasys meets the market value of publicly held shares and other initial listing requirements, except the bid price rule. Femasys said it may effect a reverse stock split, if necessary, and will monitor its share price and take actions within the prescribed period to regain compliance.

#FEMY Femasys Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement

www.stocktitan.net/news/FEMY/femasys-grante...

Femasys Secures U.S. FDA Clearance for Next-Generation FemVue Diagnostic Device Femasys (NASDAQ: FEMY) announced U.S. FDA 510(k) clearance on December 18, 2025 for its next‑generation FemVue Controlled diagnostic device.The single‑device solution combines the company’s original FemVue and FemChec technologies to provide controlled contrast delivery for fallopian tube evaluation, support multiple clinical uses, and streamline manufacturing and practice workflows. Management said the clearance advances clinician‑focused innovations and aims to strengthen the scalability and efficiency of the product portfolio.

#FEMY Femasys Secures U.S. FDA Clearance for Next-Generation FemVue Diagnostic Device

www.stocktitan.net/news/FEMY/femasys-secure...

🚀 Exciting times for #FEMY! Trading at $0.90, recent FDA approval and financing news spark optimism. With a cautious long position, consider entry at $0.88, targeting $0.95 & $1.00. Stop loss at $0.85. Mixed signals but positive sentiment! 📈 #StockMarket #FeetrAI

🚀 Exciting times for #FEMY! Trading at $0.9352 with bullish vibes from a positive MACD and 14-day RSI of 57.2. 📈 Low volume hints at caution, but potential rate cuts could boost growth sectors. Consider entering at $0.93, targeting $0.98 & $1.02. Stay sharp! #Stocks #FeetrAI

🚀 Exciting times for #FEMY! Trading at $0.965, it's riding a bullish wave with strong SMA & EMA signals. FDA approval for FemBloc trial is sparking interest! 📈 Consider entering at $0.96, targeting $1.05 & $1.10. Stay alert for updates & market shifts! #FeetrAI #Stocks

🚀 Exciting times for #FEMY! With FDA approval of its women's health device, Femasys Inc. is on the rise. Trading above key averages, bullish momentum is strong. Consider entry at $1.00 with targets at $1.15 & $1.25. Stay sharp—volatility ahead! 📈 #FeetrAI #Stocks

🚀 Exciting times for #FEMY! Bullish momentum with price above key averages and a positive MACD. Recent FDA approval boosts optimism, but watch out for dilution risks. Consider a long position at $1.00, targeting $1.10-$1.15. Stay alert for market trends! 📈 #Stocks #FeetrAI

🚀 Exciting times for #FEMY! Trading at $1.02, it's riding a bullish wave with RSI at 70.8 and above key moving averages. FDA approval sparks interest, hinting at a potential short squeeze! 🎯 Target: $1.10-$1.15. Caution: dilution risks. Stay tuned for updates! 📈 #FeetrAI

🚀 Exciting times for #FEMY! Trading at $0.99, it's above key moving averages with bullish momentum. FDA approval for FemBloc adds fuel to the fire! Consider a LONG position targeting $1.05-$1.10. Watch for volume spikes and news updates. 📈 #FeetrAI #StockMarket

🚀 Exciting times for #FEMY! With bullish momentum and trading above key moving averages, Femasys Inc. is poised for gains. FDA approval and financing news add fuel, but watch for dilution risks. Enter at $0.98, target $1.10-$1.20. Stay sharp! 📈 #FeetrAI #Stocks

🚀 Excitement builds for #FEMY as an FDA decision looms! Trading at $0.9999, bullish signals flash with a 10-day SMA of $0.8629 and RSI at 69.66. Increased volume hints at big moves. Consider entry at $0.98, targeting $1.10 & $1.20. Stay alert for FDA updates! 📈 #Stocks #FeetrAI

🚀 Exciting times for #FEMY! With bullish momentum, FDA approval, and insider confidence, this non-surgical birth control innovator is poised for gains. Consider a LONG position at $1.00, targeting $1.05 & $1.10. Stay tuned for trial updates! 📈 #FeetrAI #StockMarket

🚀 Exciting times for #FEMY! With bullish momentum and recent FDA approval, this women's health innovator is on the rise. Current price at $1.02, targeting $1.10 & $1.15. Watch for a potential short squeeze! 📈 #Stocks #Investing #FeetrAI

PharmaCyte Biotech Successfully Monetizes Femasys Stake, Strengthening Cash Position and Underscoring Strategic Capital Deployment PharmaCyte Biotech (Nasdaq:PMCB) announced it has successfully monetized its stake in Femasys (Nasdaq:FEMY), boosting its liquidity position.Proceeds lift cash and marketable securities to approximately $20 million in cash (up from $13.3 million on July 31, 2025) and the company reports roughly $25 million in marketable securities as valued in its most recent 10-Q.The company noted a recent share price of $0.65 with about 6.8 million shares outstanding and reiterated plans to pursue value-accretive investments and disciplined operations to enhance shareholder returns.

#FEMY #PMCB PharmaCyte Biotech Successfully Monetizes Femasys Stake, Strengthening Cash Position and Underscoring Strategic Capital Deployment

www.stocktitan.net/news/FEMY/pharma-cyte-bi...

Femasys Announces Third Quarter Financial Results for 2025 Femasys (NASDAQ: FEMY) reported 3Q 2025 results and multiple corporate milestones on Nov 14, 2025. Key operational highlights include FDA IDE approval to advance the final FemBloc pivotal trial, regulatory approvals in the U.K. and New Zealand, initiation of European post-market surveillance, and new distribution partnerships and initial commercial orders in Europe.Financing actions strengthened liquidity: a $12 million secured convertible notes agreement (with up to $58 million potential if warrants exercised) and an underwritten public offering raising $8 million. Financials: 3Q sales were $729,394 (+31.4% vs. 3Q2024); 9M sales were $1.480M (+41.3% YoY). Cash was approximately $4.6M with a stated cash runway into September 2026.

#FEMY Femasys Announces Third Quarter Financial Results for 2025

www.stocktitan.net/news/FEMY/femasys-announ...

Femasys Advances Global Growth with Second Partner Order for FemBloc® in Europe Femasys (NASDAQ: FEMY) announced an initial commercial order of approximately $500,000 to launch FemBloc Permanent Birth Control in France and the Benelux region through distributor Kebomed, dated Nov 10, 2025. This follows the company’s recent entry into Spain and represents continued European expansion for the non-surgical permanent contraceptive.FemBloc is described as a first‑of‑its‑kind, non‑surgical permanent contraception that places a proprietary polymer into both fallopian tubes to form permanent occlusion without anesthesia, incisions, or recovery time, positioning the product as a potentially disruptive global offering.

#FEMY Femasys Advances Global Growth with Second Partner Order for FemBloc® in Europe

www.stocktitan.net/news/FEMY/femasys-advanc...

#FEMY Femasys Secures FDA Approval to Advance Final FemBloc® Trial Phase and $12 Million Financing, with Potential to Reach $58 Million

www.stocktitan.net/news/FEMY/femasys-secure...

Femasys Announces Initiation of Post-Market Surveillance Study for FemBloc® Permanent Birth Control in Europe Femasys (NASDAQ: FEMY) announced the initiation of a post-market surveillance (PMS) clinical study for its CE-marked FemBloc Permanent Birth Control in Europe on October 22, 2025.The study is conducted under the EU Medical Device Regulation (EU MDR 2017/745, Annex XIV Part B), has approval from multiple Ethics Committees, and follows ISO 14155:2020 Good Clinical Practice and applicable national rules. FemBloc is described as a non-surgical permanent birth control using a biodegradable polymer delivery to occlude fallopian tubes without anesthesia, incisions, or recovery time, positioned to support physician adoption and reimbursement across Europe.

#FEMY Femasys Announces Initiation of Post-Market Surveillance Study for FemBloc® Permanent Birth Control in Europe

www.stocktitan.net/news/FEMY/femasys-announ...

Femasys to Exhibit at the ASRM 2025 Scientific Congress & Expo Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective to women worldwide, is pleased to announce that

#FEMY Femasys to Exhibit at the ASRM 2025 Scientific Congress & Expo

www.stocktitan.net/news/FEMY/femasys-to-exh...

Femasys Accelerates European Growth for FemBloc® with Kebomed Partnership Femasys Inc. (NASDAQ: FEMY) has announced a strategic partnership with Kebomed to commercialize its FemBloc Permanent Birth Control solution in France and Benelux countries. This partnership follows FemBloc's recent CE mark approval and targets France as the largest European market opportunity.FemBloc is a revolutionary non-surgical permanent birth control solution that uses a proprietary polymer delivery system to create natural scar tissue in fallopian tubes. The technology eliminates risks associated with surgical sterilization, including anesthesia complications and infection, while offering a more cost-effective and accessible option for women.

#FEMY Femasys Accelerates European Growth for FemBloc® with Kebomed Partnership

www.stocktitan.net/news/FEMY/femasys-accele...

Non-Surgical Birth Control Pioneer Femasys Lands $8M to Scale Revolutionary Women's Health Solutions Biotech innovator Femasys secures $8M to accelerate FemaSeed fertility and FemBloc birth control solutions. Recent wins include EU/UK approvals and $400K Spanish order for non-surgical contraception.

#FEMY Femasys Closes $8 Million in Financing to Accelerate Commercialization of Fertility and Birth Control Portfolios

www.stocktitan.net/news/FEMY/femasys-closes...

$8 Million Capital Raise: Women's Health Innovator Femasys Prices Public Offering with Warrant Package Biomedical company Femasys (NASDAQ: FEMY) prices offering of 10.4M shares at $0.36, plus pre-funded warrants for 11.75M shares. Net proceeds to fund commercial expansion and product development.

#FEMY Femasys Announces Pricing of $8.0 Million Underwritten Public Offering

www.stocktitan.net/news/FEMY/femasys-announ...

Femasys Secures UK Regulatory Approval of FemBloc Permanent Birth Control Femasys Inc. (NASDAQ: FEMY) has secured MHRA approval for its FemBloc Permanent Birth Control in the United Kingdom, following its recent CE mark approval for Europe. This regulatory milestone validates the product's safety, quality, and effectiveness standards for the UK market.FemBloc represents a revolutionary non-surgical permanent birth control solution that utilizes a patented delivery system to place a proprietary blended polymer in the fallopian tubes. The polymer naturally degrades and forms scar tissue for permanent occlusion, offering significant advantages over surgical sterilization by eliminating anesthesia risks, infection concerns, and recovery time.The UK approval positions Femasys to pursue strategic partnerships for commercialization in one of Europe's largest healthcare markets, particularly through the National Health Service (NHS).

#FEMY Femasys Secures UK Regulatory Approval of FemBloc Permanent Birth Control

www.stocktitan.net/news/FEMY/femasys-secure...

Femasys Announces Second Quarter Financial Results for 2025 Femasys Inc. (NASDAQ: FEMY) reported Q2 2025 financial results with notable regulatory achievements and commercial expansion. Sales increased 84.8% to $409,268 in Q2 2025, driven by FemaSeed and FemVue products. The company secured significant milestones including EU approval for FemBloc, their non-surgical permanent birth control solution, with a $400,000 initial order from Spain.The quarter saw regulatory approvals in Australia and New Zealand for FemaSeed and FemVue, alongside a new partnership with Carolinas Fertility Institute. However, Femasys reported a net loss of $4.6 million ($0.16 per share) and had $3.2 million in cash as of June 30, 2025, expected to fund operations only into early Q4 2025.

#FEMY Femasys Announces Second Quarter Financial Results for 2025

www.stocktitan.net/news/FEMY/femasys-announ...

Femasys Secures First European Order for FemBloc, Marking Strategic Milestone in Global Expansion Femasys (NASDAQ: FEMY) has secured its first European commercial order for FemBloc, its revolutionary non-surgical permanent birth control solution, with a $400,000 USD order from Spain. The company has partnered with Comercial Medico Quirúrgica and Durgalab as distributors, leveraging their experience with similar women's health technologies.FemBloc represents a breakthrough in permanent contraception, utilizing a proprietary polymer delivery system that creates natural scar tissue in the fallopian tubes. This non-surgical approach eliminates risks associated with traditional surgical sterilization, offering a safer, more accessible, and cost-effective alternative for women seeking permanent birth control.

#FEMY Femasys Secures First European Order for FemBloc, Marking Strategic Milestone in Global Expansion

www.stocktitan.net/news/FEMY/femasys-secure...